行情

FLXN

FLXN

Flexion
NASDAQ

实时行情|Nasdaq Last Sale

14.74
-0.26
-1.70%
已收盘, 16:11 10/22 EDT
开盘
15.16
昨收
14.99
最高
15.40
最低
14.67
成交量
62.27万
成交额
--
52周最高
18.00
52周最低
8.76
市值
5.62亿
市盈率(TTM)
-3.4438
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FLXN 新闻

  • 黑石集团第三季度净流入204亿美元,同比减少15%。管理资产5,540亿美...
  • 新浪财经.2小时前
  • 美药企称研发世界首款“有效”阿兹海默药 仍待获批
  • 澎湃新闻.2小时前
  • 要脸书解密用户聊天消息 印度政府:恐怖分子无隐私权
  • 澎湃新闻.2小时前
  • 携程将于11月14日发布2019年第三季度财报
  • 新浪科技.2小时前

更多

所属板块

生物技术和医学研究
+0.52%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

FLXN 简况

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
展开

Webull提供Flexion Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。